Next generation antidepressants with novel mechanisms for treatment resistant depression

Mu Hong Chen; Pei Chi Tu; Tung Ping Su

doi:10.1016/bs.pbr.2023.02.005

Next generation antidepressants with novel mechanisms for treatment resistant depression

Mu Hong Chen^*
, Pei Chi Tu
, Tung Ping Su

^*此作品的通信作者

醫學系精神學科

研究成果: Chapter › 同行評審

2 引文斯高帕斯（Scopus）

摘要

Evidence has suggested that the modulation of N-methyl-D-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.

原文	English
主出版物標題	Treatment-Resistant Depression Part A
編輯	Cheng-Ta Li, Chih-Ming Cheng
發行者	Elsevier B.V.
頁面	149-168
頁數	20
ISBN（列印）	9780323957786
DOIs	https://doi.org/10.1016/bs.pbr.2023.02.005
出版狀態	Published - 1月 2023

出版系列

名字	Progress in Brain Research
卷	278
ISSN（列印）	0079-6123
ISSN（電子）	1875-7855

UN SDG

此研究成果有助於以下永續發展目標

SDG 3 良好的健康和福祉

存取文件

10.1016/bs.pbr.2023.02.005

其它文件與鏈接

Link to publication in Scopus

引用此

@inbook{cdde9ec53f464c65a2c958e873cbd1e1,

title = "Next generation antidepressants with novel mechanisms for treatment resistant depression",

abstract = "Evidence has suggested that the modulation of N-methyl-D-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.",

keywords = "Consciousness, Depression, Ketamine, Neuroplasticity, Novel antidepressants, Psilocybin, Psychedelics",

author = "Chen, \{Mu Hong\} and Tu, \{Pei Chi\} and Su, \{Tung Ping\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = jan,

doi = "10.1016/bs.pbr.2023.02.005",

language = "English",

isbn = "9780323957786",

series = "Progress in Brain Research",

publisher = "Elsevier B.V.",

pages = "149--168",

editor = "Cheng-Ta Li and Chih-Ming Cheng",

booktitle = "Treatment-Resistant Depression Part A",

address = "荷蘭",

}

TY - CHAP

T1 - Next generation antidepressants with novel mechanisms for treatment resistant depression

AU - Chen, Mu Hong

AU - Tu, Pei Chi

AU - Su, Tung Ping

PY - 2023/1

Y1 - 2023/1

N2 - Evidence has suggested that the modulation of N-methyl-D-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.

AB - Evidence has suggested that the modulation of N-methyl-D-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.

KW - Consciousness

KW - Depression

KW - Ketamine

KW - Neuroplasticity

KW - Novel antidepressants

KW - Psilocybin

KW - Psychedelics

UR - https://www.scopus.com/pages/publications/85150360596

U2 - 10.1016/bs.pbr.2023.02.005

DO - 10.1016/bs.pbr.2023.02.005

M3 - Chapter

C2 - 37414491

AN - SCOPUS:85150360596

SN - 9780323957786

T3 - Progress in Brain Research

SP - 149

EP - 168

BT - Treatment-Resistant Depression Part A

A2 - Li, Cheng-Ta

A2 - Cheng, Chih-Ming

PB - Elsevier B.V.

ER -

Next generation antidepressants with novel mechanisms for treatment resistant depression

摘要

出版系列

UN SDG

存取文件

其它文件與鏈接

指紋

引用此